 CAMBRIDGE, Mass., Sept. 22, 2021 PRNewswire -- Leap Therapeutics, Inc. Nasdaq:LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of 2.85 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of 2.849 per pre-funded warrant, which represents the per share public offering price for the common stock less the 0.001 per share exercise price for each pre-funded warrant. 